Zhongheng Group (600252.SH) announced that its indirectly held subsidiary has obtained two medical device registration certificates.

Zhongheng Group (600252.SH) announced that recently, Hainan Lemei Medical Device Co., Ltd. (“Lemei Medical Device”), a subsidiary of Chongqing Lemei Pharmaceutical Co., Ltd.—which is itself a majority-owned subsidiary of the company—received two Medical Device Registration Certificates issued by the Hainan Provincial Medical Products Administration. The certified products are a video laryngoscope for anesthesia and single-use laryngoscope blades, both of which are endoscopic devices developed by Lemei Medical Device. These products enable medical personnel to perform accurate airway intubation, thereby facilitating clinical diagnosis and treatment of patients.

Zhitong FinanceJun 12 18:40

Zhongheng Group (600252.SH) and relevant responsible persons received a warning letter from the Guangxi Securities Regulatory Bureau.

Zhongheng Group (600252.SH) announced that on June 12, 2026, the company received a Decision on Issuing a Warning Letter to Guangxi Wuzhou Zhongheng Group Co., Ltd. and Relevant Responsible Persons (hereinafter referred to as the "Warning Letter") from the Guangxi Regulatory Bureau of the China Securities Regulatory Commission (hereinafter referred to as the "Guangxi CSRC Bureau").

Zhitong FinanceJun 12 18:33

Zhongheng Group (600252.SH): Currently has no strategic plan to establish business operations in the brain-computer interface field.

Gelonghui, June 10 — Zhongheng Group (SHA: 600252) stated on an interactive platform that, as of now, the company does not have any strategic plans to enter the brain-computer interface sector. Should the company formulate any relevant investment plans that meet disclosure thresholds, it will promptly fulfill its information disclosure obligations.

Gelonghui FinanceJun 10 16:14

USD 1.861 billion! Memory sector dark horse signs massive long-term procurement agreement | Selected After-Hours Announcements

A leading memory chip stock signed a long-term procurement order worth USD 1.86 billion; the global new energy vehicle leader responded to being placed on a U.S. related list; a CXO giant plans a RMB 1 billion share repurchase...

Golden10 DataJun 9 20:54

Limei Pharmaceuticals (300006.SZ): Shareholder voting rights entrustment expired

Gelonghui, June 9 — Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE: 300006) announced that Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as “Zhongheng Group”), the company’s controlling shareholder, and Mr. Qiu Yu, a shareholder of the company, entered into a Voting Rights Entrustment Agreement on June 4, 2024. Pursuant to the agreement, Mr. Qiu Yu has exclusively and irrevocably entrusted Zhongheng Group with the voting rights attached to his 118,254,000 shares of the company (representing 11.20% of the company’s total share capital). The term of the voting rights entrustment shall commence on the effective date of the agreement and expire on June 7, 2026. During the term of the voting rights entrustment, due to judicial enforcement or other reasons, Mr. Qiu Yu

Gelonghui FinanceJun 9 20:47

Express News | Zhongheng Group: Its controlling subsidiary intends to cease payment of the subscribed capital contribution of RMB 60 million to the fund.

BreakingsJun 9 19:31